Back to mobile site

Corcept Therapeutics (CORT) Tops Q4 EPS by 3c

January 30, 2017 4:06 PM EST

Corcept Therapeutics (NASDAQ: CORT) reported Q4 GAAP EPS of $0.04, $0.03 better than the analyst estimate of $0.01. Revenue for the quarter came in at $23.8 million versus the consensus estimate of $23.46 million.

GUIDANCE:

Corcept Therapeutics sees FY2017 revenue of $115-125 million.

For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance

Related Entities

Earnings